Navigation Links
Alzheimer's Drug Discovery Foundation Supports Axxam To Develop Novel Therapeutics for Alzheimer's Disease
Date:6/22/2011

NEW YORK, June 22, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation.

(Logo: http://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The award will fund a drug discovery project to identify compounds that block the puringeric receptor, P2X7, which is involved in inflammation in the brain.  One of the characteristic features of Alzheimer's disease is a robust inflammatory response involving over-activation of specialized brain cells called microglia and the release of pro-inflammatory signals associated with the deposition of Alzheimer's disease plaques in the brain.  These pro-inflammatory signals are closely associated with the P2X7 receptor, putting this novel target at the heart of brain inflammation.

"Compounds that block P2X7 may treat brain inflammation and can potentially be useful in the treatment of Alzheimer's disease and other neurodegenerative diseases," said Howard Fillit, MD, Executive Director, ADDF.  "P2X7 is a novel target and we are excited to fund the program and investigate its therapeutic potential."

"We are pleased to be selected by the ADDF for this peer-reviewed grant, which recognizes the quality of our research capabilities in the challenging field of neuroinflammation." Said Stefan Lohmer, co-founder and CEO of Axxam.  "We are looking forward to working with the ADDF team and moving our Alzheimer's disease program forward."

For more information about the ADDF or to speak with Dr. Fillit, please contact Filomena Machleder at 212-901-8004 or fmachleder@alzdiscovery.org.  For more information about Axxam, please contact Stefan Lohmer, PhD, CEO, Axxam at +39 02 2105622 or '/>"/>

SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
2. Alzheimers Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
3. GE Discovery ST Installed at Imaging Healthcare Specialists
4. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
5. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
6. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
7. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
8. BioSurplus Selected to Liquidate Discovery Laboratory Equipment
9. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
10. Reportlinker Adds The Drug Discovery Outsourcing Market
11. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Pa. , May 4, 2015 DePuy ... Dura Repair, the first commercially available biosynthesized dural ... Synthes CMF is a part of the DePuy Synthes ... is a tissue membrane that covers and protects the ... be cut to allow surgeons to access the brain. ...
(Date:5/4/2015)... ANGELES , May 4, 2015 Former ... FOX News online last week where he discussed Theradome™, ... to be FDA-cleared. The FOX segment shows firsthand how, ... and affordable hair loss solution that will not require ... stimulates the mitochondria at the base of the hair ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ ... announced that it intends to dividend to its stockholders ... of a definitive licensing agreement to license its RapidMist™ ... ) (OTCQB:SMFI). As announced on April 23, ... in respect of the licensing of its RapidMist™ buccal ...
Breaking Medicine Technology:DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:5/4/2015)... HHT is a rare but cruel ... it can have seemingly mild symptoms like frequent nosebleeds, ... Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary disorder resulting ... capillary connections between an artery and a vein. These ... but may also be present in the lungs, brain ...
(Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “ LiveSchool ... monthly AppWatch, which takes a look at the latest ... and Windows. Joe Toohey, the host of AppWatch and ... viewers how this application allows teachers to reward students ... than some realize, especially in the classroom. And ...
(Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... While the World Cup is the most known soccer ... the International Champions Cup is one of the biggest tournaments ... record for soccer in the United States set when Manchester ... University of Michigan. This year, the defending champion Manchester United ...
Breaking Medicine News(10 mins):Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4
... , ... Strong Backbone for Victory: Cortical Concepts Wins ,Wharton Business Plan Competition Michelson Grand ... “People’s Choice” Award with Private Sales for Co-eds, , ... Philadelphia, PA (PRWEB) April 29, ...
... ... Science and Technology Policy, will bring together leaders in open innovation , ... Washington, DC (Vocus) -- This ... Grant Making”, a public-private strategy session jointly hosted by the White House Office on ...
... Athens, Ga. A team of researchers at the University ... the next five years from the National Institutes of Health ... may prevent drug abuse relapse. "Drug abuse is ... aspects of treating addiction is preventing the relapse caused by ...
... ... awarded a $4.2 million grant from the Ontario Ministry of Research and Innovation’s Biopharmaceutical ... expansion of its bio-manufacturing facility in Mississauga, Ontario, Canada. , ... Toronto, ON (Vocus) April 30, 2010 -- ...
... how the brain communicates with limbs, researcher says , THURSDAY, ... a phenomenon known as mirror movements has been identified by ... move one side of their body without moving the other. ... the same movement occurs unintentionally in the left hand. , ...
... ... has developed a unique caregiver testing program to measure the preparedness of home care ... ... 29, 2010 -- The National Private Duty Association (NPDA), a non-profit organization comprised of ...
Cached Medicine News:Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 2Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 3Health News:Prize4Life Featured in Major Innovation/Prize National Conference 2Health News:Prize4Life Featured in Major Innovation/Prize National Conference 3Health News:UGA, Emory to study how exercise may prevent drug abuse relapse 2Health News:Therapure Awarded $4.2 Million BIP Grant from the Ontario Government 2Health News:Scientists Find Cause of Involuntary Mirror Movements 2Health News:Association Advocates Testing for Home Care Workers 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: